

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Comparison 3: simvastatin	placebo	Relative (95% CI)	Absolute (95% CI)		
Cognitive abilities (follow up: 52 weeks; assessed with: Neuropsychological Assessment of Dementia in Intellectual Disabilities battery)												
1	randomised trials	not serious	not serious	not serious	very serious <sup>1</sup>	none	10	11	-	MD 10 higher (0.4 lower to 1.6 higher)	⊕⊕○○ LOW	CRITICAL
Quality of life – not reported												
-	-	-	-	-	-	-					-	CRITICAL
Community participation and meaningful occupation – not reported												
-	-	-	-	-	-	-					-	CRITICAL
Adaptive functioning (follow up: 52 weeks; assessed with: AAMR: ABS)												
1	randomised trials	not serious	not serious	not serious	very serious <sup>1</sup>	none	10	11	-	MD 0.7 higher (0 to 1.4 higher)	⊕⊕○○ LOW	IMPORTANT

1. Downgraded two levels for serious imprecision (wide confidence interval) and small number of events.